In an adult patient with chronic insomnia, which is more appropriate: Belsomra (suvorexant) or Dayvigo (lemborexant), considering the pattern of sleep disturbance, hepatic function, and risk of next‑day sedation?

Belsomra vs Dayvigo for Chronic Insomnia

For most adults with chronic insomnia, Dayvigo (lemborexant) is the preferred dual orexin receptor antagonist over Belsomra (suvorexant), based on superior efficacy in reducing sleep onset latency and total sleep time, with a potentially more favorable side effect profile, particularly regarding next-day somnolence.

Evidence-Based Rationale

Efficacy Comparison

The most recent and highest-quality network meta-analysis 1 directly comparing all three FDA-approved dual orexin receptor antagonists (DORAs) demonstrates that lemborexant 10 mg outperformed suvorexant 20/15 mg on the primary outcome of subjective time to sleep onset (sTSO standardized mean difference: -0.430 vs -0.164 compared to placebo). Similarly, lemborexant showed superior efficacy for subjective total sleep time (sTST: -0.475 for lemborexant 10 mg vs -0.340 for suvorexant 20/15 mg) 2.

An earlier 2020 network meta-analysis 2 of 3,237 patients confirmed that lemborexant 10 mg had the largest effect size compared with placebo for all primary sleep outcomes including sTSO, sTST, and subjective wake after sleep onset (sWASO), consistently outperforming suvorexant across these measures.

Safety and Tolerability Profile

Real-world clinical data from Japan 3 involving 108 patients found no significant difference in effectiveness between the two medications (CGI-I scores: 3.05 for suvorexant vs 3.38 for lemborexant, p=0.10), but lemborexant demonstrated a trend toward fewer side effects (2.9% vs 12.5%, p=0.10). Notably, patients who switched from suvorexant to lemborexant due to persistent insomnia showed improvement without experiencing side effects after the switch.

A 2022 study 4 of 77 patients demonstrated that switching from suvorexant to lemborexant significantly improved difficulty initiating sleep (odds ratio = 0.036, P = 0.008), with no serious adverse events and high tolerability.

Pattern-Specific Recommendations

For sleep maintenance insomnia: Both medications are FDA-approved and effective 55. The 2017 AASM guideline 66 provides a WEAK recommendation for suvorexant specifically for sleep maintenance insomnia. However, lemborexant is FDA-approved for both sleep onset AND maintenance difficulties 55, making it more versatile.

For sleep onset insomnia: Lemborexant demonstrates superior efficacy based on network meta-analysis data 21, with significantly better reduction in sleep onset latency compared to suvorexant.

For mixed insomnia (both onset and maintenance): Lemborexant is the clear choice, as it is FDA-approved for both components 55 and shows superior efficacy across all sleep parameters.

Clinical Decision Algorithm

Step 1: Assess Sleep Pattern

• Predominantly sleep maintenance issues: Either medication acceptable, but lemborexant preferred for superior overall efficacy
• Predominantly sleep onset issues: Choose lemborexant (superior sTSO reduction)
• Mixed onset and maintenance: Choose lemborexant (FDA-approved for both, superior across all parameters)

Step 2: Evaluate Hepatic Function

• Normal hepatic function: Start lemborexant 5 mg or suvorexant 10 mg
• Moderate hepatic impairment: Both require dose adjustment; lemborexant 5 mg maximum, suvorexant 5 mg maximum
• Severe hepatic impairment: Avoid both medications

Step 3: Assess Next-Day Sedation Risk

• High-risk patients (elderly, driving requirements, complex morning tasks): Start with lemborexant 5 mg - lower somnolence risk than suvorexant in comparative studies 3
• Standard-risk patients: Lemborexant 5-10 mg preferred
• Note: The 2025 meta-analysis 1 found lemborexant 10 mg and suvorexant 20/15 mg both associated with higher somnolence versus placebo, but real-world data suggests lemborexant may be better tolerated 3

Step 4: Dosing Strategy

Lemborexant (preferred):

• Start: 5 mg nightly
• Titrate: May increase to 10 mg if needed for efficacy
• Maximum: 10 mg nightly

Suvorexant (alternative):

• Start: 10 mg nightly (5 mg in elderly ≥65 years)
• Titrate: May increase to 20 mg (15 mg in elderly) if needed
• Maximum: 20 mg nightly (15 mg in elderly)

Important Safety Considerations

Common Pitfalls to Avoid

1. Somnolence risk: Both medications carry FDA warnings about next-day impairment 5. Counsel patients to allow at least 7 hours for sleep and avoid driving or operating machinery until they know how the medication affects them.

2. Complex sleep behaviors: Both DORAs can cause sleep-walking, sleep-driving, and other complex behaviors 5. Discontinue immediately if these occur.

3. Sleep paralysis and hallucinations: Lemborexant trials reported sleep paralysis in 1.6% (10 mg) and hypnagogic hallucinations in 0.7% (10 mg) 5. Warn patients about these potential experiences.

4. Respiratory compromise: Both medications have been studied in mild-moderate OSA and COPD 57. A 2026 post-hoc analysis 7 showed lemborexant improved insomnia severity in patients with mild OSA without significantly impacting respiratory function, but use caution in moderate-severe respiratory disease.

5. Suicidal ideation: The FDA label for lemborexant 5 notes higher rates of suicidal ideation in trials (0.3-0.4% vs 0.2% placebo). Screen for depression and monitor closely in at-risk patients.

Long-Term Use Considerations

A 2026 systematic review 8 of long-term DORA use (≥6 months) in 3,546 participants found that both medications provide sustained improvements in subjective sleep outcomes with acceptable safety profiles. However, adverse events were higher at 12 months compared to 6 months, and higher doses showed increased discontinuation rates. This supports starting with lower doses (lemborexant 5 mg, suvorexant 10 mg) and titrating only if necessary.

Guideline Context

The 2017 AASM guideline 6666 provides only a WEAK recommendation for suvorexant for sleep maintenance insomnia, as lemborexant was not yet FDA-approved at the time of publication. The 2016 ACP evidence report 9 similarly only evaluated suvorexant among the orexin antagonists. More recent evidence clearly favors lemborexant based on head-to-head network meta-analyses 21 and real-world comparative effectiveness data 34.

A 2026 primary care review 10 confirms that dual orexin receptor antagonists are evidence-based options for insomnia, with the caveat that pharmacologic therapy should ideally be short-term and combined with cognitive behavioral therapy for insomnia (CBT-I) when possible.